Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
113 hedge funds and large institutions have $169M invested in Cymabay Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 37 reducing their positions, and 17 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 113 → 113 (0)
25% less capital invested
Capital invested by funds: $227M → $169M (-$57.8M)
38% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 37
48% less call options, than puts
Call options by funds: $1.41M | Put options by funds: $2.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.13M |
| 2 |
CC
Commodore Capital
New York
|
+$2.52M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$526K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$453K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$17.4M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$2.02M |
| 3 |
Two Sigma Advisers
New York
|
-$1.83M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.51M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$1.41M |
CBAY Hedge Fund Activity: Q3 2021 in Review
113 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2021, worth a combined $169M — down 25% from $227M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CBAY positions and 17 closed out — a net gain of 1 holder — while 23 added to existing stakes and 37 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $5.13M. The largest seller was Boxer Capital, exiting entirely with an estimated $17.4M sold.
- 113 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $169M of Cymabay Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
- 18 funds opened new Cymabay Therapeutics positions in Q3 2021 and 17 closed out, a net change of +1 holder.
- The largest Cymabay Therapeutics buyer in Q3 2021 was JP Morgan Chase, an estimated $5.13M added.
- The largest Cymabay Therapeutics seller in Q3 2021 was Boxer Capital, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2021.